130 related articles for article (PubMed ID: 31639687)
1. Lack of Influence by CYP3A4 and CYP3A5 Genotypes on Pain Relief by Hydrocodone in Postoperative Cesarean Section Pain Management.
Hosseinnejad K; Yin T; Gaskins JT; Stauble ME; Wu Y; Jannetto P; Langman LL; Jortani SA
J Appl Lab Med; 2019 May; 3(6):954-964. PubMed ID: 31639687
[TBL] [Abstract][Full Text] [Related]
2. Hydrocodone in postoperative personalized pain management: pro-drug or drug?
Stauble ME; Moore AW; Langman LJ; Boswell MV; Baumgartner R; McGee S; Metry J; Jortani SA
Clin Chim Acta; 2014 Feb; 429():26-9. PubMed ID: 24269714
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
4. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.
Boswell MV; Stauble ME; Loyd GE; Langman L; Ramey-Hartung B; Baumgartner RN; Tucker WW; Jortani SA
Pain Physician; 2013; 16(3):E227-35. PubMed ID: 23703421
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys.
Lelas S; Wegert S; Otton SV; Sellers EM; France CP
Drug Alcohol Depend; 1999 May; 54(3):239-49. PubMed ID: 10372797
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 Pharmacogenetics Testing and Post-Cesarean Section Pain Scores-a Preliminary Study.
Ribeiro C; Quinta R; Raposo A; Valentim A; Albuquerque J; Grazina M
Pain Med; 2019 Feb; 20(2):359-368. PubMed ID: 29546421
[TBL] [Abstract][Full Text] [Related]
8. Urinary hydrocodone and metabolite distributions in pain patients.
Barakat NH; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Sep; 38(7):404-9. PubMed ID: 24836897
[TBL] [Abstract][Full Text] [Related]
9. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of norhydrocodone: an active metabolite of hydrocodone.
Navani DM; Yoburn BC
J Pharmacol Exp Ther; 2013 Nov; 347(2):497-505. PubMed ID: 23995596
[TBL] [Abstract][Full Text] [Related]
11. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
Yin OQ; Tomlinson B; Chow MS
J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.
Otton SV; Schadel M; Cheung SW; Kaplan HL; Busto UE; Sellers EM
Clin Pharmacol Ther; 1993 Nov; 54(5):463-72. PubMed ID: 7693389
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
15. Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine.
Cao JM; Ma JD; Morello CM; Atayee RS; Best BM
J Opioid Manag; 2014; 10(3):177-86. PubMed ID: 24944068
[TBL] [Abstract][Full Text] [Related]
16. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
17. Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.
Tomkins DM; Otton SV; Joharchi N; Li NY; Balster RF; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Mar; 280(3):1374-82. PubMed ID: 9067326
[TBL] [Abstract][Full Text] [Related]
18. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.
Yee MM; Josephson C; Hill CE; Harrington R; Castillejo MI; Ramjit R; Osunkwo I
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e301-5. PubMed ID: 23619115
[TBL] [Abstract][Full Text] [Related]
20. Observations on the urine metabolic profile of codeine in pain patients.
Yee DA; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Mar; 38(2):86-91. PubMed ID: 24396053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
